Post-streptococcal glomerulonephritis epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
Manpreet Kaur (talk | contribs)
No edit summary
Manpreet Kaur (talk | contribs)
No edit summary
 
(18 intermediate revisions by the same user not shown)
Line 2: Line 2:
{{Post-streptococcal glomerulonephritis}}
{{Post-streptococcal glomerulonephritis}}


{{CMG}} {{AE}} {{MKK}}
==Overview==
==Overview==
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].


OR
The incidence of [[post-streptococcal glomerulonephritis]] is approximately 9.5 to 28.5 per 100,000 individuals worldwide. The case-fatality rate of [[post-streptococcal glomerulonephritis]] is approximately 2 percent in India and 0.08 percent in Turkey. It commonly affects children with age between 5 to 12 years. The incidence of [[post-streptococcal glomerulonephritis]] increases in older people age greater than 60 years. It commonly affects children with age between 5 to 12 years. Men are more commonly affected by [[post-streptococcal glomerulonephritis]] than women. The majority of [[post-streptococcal glomerulonephritis]] cases are reported in developing countries.


Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
==Epidemiology and Demographics==
===Incidence===
*The incidence of [[post-streptococcal glomerulonephritis]] is approximately 9.5 to 28.5 per 100,000 individuals worldwide.<ref name="pmid16253886">{{cite journal |vauthors=Carapetis JR, Steer AC, Mulholland EK, Weber M |title=The global burden of group A streptococcal diseases |journal=Lancet Infect Dis |volume=5 |issue=11 |pages=685–94 |date=November 2005 |pmid=16253886 |doi=10.1016/S1473-3099(05)70267-X |url=}}</ref>


OR
===Case-fatality rate===
*The case-fatality rate of post-streptococcal glomerulonephritis is approximately 2 percent in India and 0.08 percent in Turkey.<ref name="pmid21371205">{{cite journal |vauthors=Jackson SJ, Steer AC, Campbell H |title=Systematic Review: Estimation of global burden of non-suppurative sequelae of upper respiratory tract infection: rheumatic fever and post-streptococcal glomerulonephritis |journal=Trop. Med. Int. Health |volume=16 |issue=1 |pages=2–11 |date=January 2011 |pmid=21371205 |doi=10.1111/j.1365-3156.2010.02670.x |url=}}</ref>


Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
===Age===
==Natural History, Complications, and Prognosis==
*The incidence of [[post-streptococcal glomerulonephritis]] increases in older people age greater than 60 years.
*It commonly affects [[children]] with age between 5 to 12 years.


===Natural History===
===Race===
*The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
*There is no racial predilection to [[post-streptococcal glomerulonephritis]].
*The symptoms of (disease name) typically develop ___ years after exposure to ___.
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].


===Complications===
===Gender===
*Common complications of [disease name] include:
*Men are more commonly affected by post-streptococcal glomerulonephritis than women.
**[Complication 1]
**[Complication 2]
**[Complication 3]


===Prognosis===
===Region===
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
*The majority of post-streptococcal glomerulonephritis cases are reported in developing countries.<ref name="pmid18667731">{{cite journal |vauthors=Rodriguez-Iturbe B, Musser JM |title=The current state of poststreptococcal glomerulonephritis |journal=J. Am. Soc. Nephrol. |volume=19 |issue=10 |pages=1855–64 |date=October 2008 |pmid=18667731 |doi=10.1681/ASN.2008010092 |url=}}</ref>
*Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
*[Subtype of disease/malignancy] is associated with the most favorable prognosis.
*The prognosis varies with the [characteristic] of the tumor; [subtype of disease/malignancy] have the most favorable prognosis.


==References==
==References==

Latest revision as of 19:51, 14 June 2018

Post-streptococcal glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Post-streptococcal glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Post-streptococcal glomerulonephritis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Post-streptococcal glomerulonephritis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Post-streptococcal glomerulonephritis epidemiology and demographics

CDC on Post-streptococcal glomerulonephritis epidemiology and demographics

Post-streptococcal glomerulonephritis epidemiology and demographics in the news

Blogs on Post-streptococcal glomerulonephritis epidemiology and demographics

Directions to Hospitals Treating Post-streptococcal glomerulonephritis

Risk calculators and risk factors for Post-streptococcal glomerulonephritis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

The incidence of post-streptococcal glomerulonephritis is approximately 9.5 to 28.5 per 100,000 individuals worldwide. The case-fatality rate of post-streptococcal glomerulonephritis is approximately 2 percent in India and 0.08 percent in Turkey. It commonly affects children with age between 5 to 12 years. The incidence of post-streptococcal glomerulonephritis increases in older people age greater than 60 years. It commonly affects children with age between 5 to 12 years. Men are more commonly affected by post-streptococcal glomerulonephritis than women. The majority of post-streptococcal glomerulonephritis cases are reported in developing countries.

Epidemiology and Demographics

Incidence

Case-fatality rate

  • The case-fatality rate of post-streptococcal glomerulonephritis is approximately 2 percent in India and 0.08 percent in Turkey.[2]

Age

Race

Gender

  • Men are more commonly affected by post-streptococcal glomerulonephritis than women.

Region

  • The majority of post-streptococcal glomerulonephritis cases are reported in developing countries.[3]

References

  1. Carapetis JR, Steer AC, Mulholland EK, Weber M (November 2005). "The global burden of group A streptococcal diseases". Lancet Infect Dis. 5 (11): 685–94. doi:10.1016/S1473-3099(05)70267-X. PMID 16253886.
  2. Jackson SJ, Steer AC, Campbell H (January 2011). "Systematic Review: Estimation of global burden of non-suppurative sequelae of upper respiratory tract infection: rheumatic fever and post-streptococcal glomerulonephritis". Trop. Med. Int. Health. 16 (1): 2–11. doi:10.1111/j.1365-3156.2010.02670.x. PMID 21371205.
  3. Rodriguez-Iturbe B, Musser JM (October 2008). "The current state of poststreptococcal glomerulonephritis". J. Am. Soc. Nephrol. 19 (10): 1855–64. doi:10.1681/ASN.2008010092. PMID 18667731.

Template:WH